尽管收入大幅下降,亏损持续持续,但Alector公司在2025年第四季度的收益估计超过了预期. Alector beat earnings estimates in Q4 2025 despite a steep revenue drop and continued losses.

Alector(NASDAQ:ALEC)于2026年2月25日报告了2025年的Q4收入,每股亏损0.34美元,比预期高出0.05美元。 Alector (NASDAQ:ALEC) reported Q4 2025 earnings on February 25, 2026, posting a loss of $0.34 per share, beating expectations by $0.05. 收入为326万美元,与一年前的5 424万美元相比急剧下降。 Revenue was $3.26 million, down sharply from $54.24 million a year earlier. 该公司仍然无利可图,负利润率和物价与收益比率为-2.23。 The company remains unprofitable, with negative margins and a price-to-earnings ratio of -2.23. 尽管收入有所节减,但由于交易量增加,股票略有上升,达到2.39美元。 Despite the earnings beat, shares rose slightly to $2.39 on increased trading volume. 专注于神经退行性疾病的临床阶段生物技术公司Alector继续面临收入波动. Alector, a clinical-stage biotech focused on neurodegenerative diseases, continues to face revenue volatility. 机构所有权仍高居85.83%,12月有一些内部销售。 Institutional ownership remains high at 85.83%, with some insider sales in December. 分析员对“持股”共识和3.25美元价格目标的看法参差不齐。 Analysts maintain a mixed outlook with a "hold" consensus and a $3.25 price target.